



NEWS RELEASE

FOR IMMEDIATE RELEASE

Contact: Ronald Trahan, APR, President, Ronald Trahan Associates Inc., +1-508-359-4005,x108

STENTYS expands its product offerings for treating heart attacks

PRINCETON, N.J., and PARIS, May 14, 2012 — **STENTYS S.A. ([STNT.PA](#))**, a medical technology company commercializing **the world's first and only Self-Apposing® Stent to treat Acute Myocardial Infarction (AMI)**, announced today that it is launching a thrombectomy device (aspiration catheter) called **STENTYS AC**.

Heart attacks are caused by the occlusion of a coronary artery due to clot formation. The European Society of Cardiology (ESC) recommends that cardiologists try removing as much clot chunks as possible prior to implanting a stent in order to minimize distal embolization (blockage of downstream vessels). STENTYS AC is designed to safely recover debris and can be used in concert with its Self-Apposing devices, STENTYS BMS and STENTYS DES.

“Coronary thrombectomy devices are a \$40 million market and we are very pleased to offer our customers a device with the best aspiration power on the market to be used with our breakthrough Self-Apposing Stents for treating AMI,” said **Gonzague Issenmann**, CEO of STENTYS. “STENTYS is building a portfolio to offer the complete AMI solution to the cath lab”

About STENTYS

Based in Princeton, N.J., and Paris, STENTYS has developed a new generation of stents to treat acute myocardial infarction (AMI) and bifurcation lesions. Founded by **Jacques Séguin, M.D., Ph.D.** and **Gonzague Issenmann**, STENTYS received CE-marking for its flagship products in 2010. Its *Self-Apposing* stent adapts to the anatomic changes of arteries in the post-infarction phase and thus prevents the *malapposition* problem associated with conventional stents. STENTYS has commenced marketing activities in several European countries.

This announcement is not an offer for sale of securities in the United States. The securities referred to herein have not been offered or sold in the United States and may not be offered or sold in the United States of America, except pursuant to a registration statement under the U.S. Securities Act of 1933, as amended (the "Securities Act"), or pursuant to an exemption from registrations thereunder. This press release is being issued pursuant to and in accordance with Rule 135c under the Securities Act.

#####